Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trialGeorgina V. Long, Dirk Schadendorf, Uwe Trefzer et al.|The Lancet Oncology|2012Cited by 906
Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV MelanomaAxel Hauschild, Ulrich Keilholz, Alexander M.M. Eggermont et al.|Journal of Clinical Oncology|2009Cited by 545
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)Poulam M. Patel, Alan Spatz, Stefan Suciu et al.|European Journal of Cancer|2011Cited by 210